November/December 2015

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Study assessed chemotherapy use in patients with chronic myelogenous leukemia (CML) to determine how use of CML-specific tests impacted drug selection and modification.

Although the focus in drug trends has primarily been on unit cost, it is time we look at the other factors involved, including value and quality of life.

In the United States, adult immunization rates are substandard. Opportunities exist to improve these rates trough quality performance measurement, but not without challenges.

This study applied a validated algorithm to estimate the effectiveness and costs of the index biologic used by 4696 US veterans with rheumatoid arthritis.

A national community-level study of Medicare patients with advanced non-small cell lung cancer found that adding targeted therapy to chemotherapy regimens was not cost-effective.

A fundamental hurdle in the race for new and better treatments is the lengthy and costly development and review process.

For Medicare plans, the 2015/2016 program audit protocol updates address many of the issues and questions raised with the previous protocols, but may result in additional challenges.